Singapore Uterine Cancer Market Size & Outlook, 2025-2033


Singapore Uterine Cancer Market Insights

  • Reed Intelligence analysis indicates that the Singapore Uterine Cancer Market size, valued at USD 26.98 Million in 2024, is expected to expand to USD 42.01 Million by 2033.
  • The Singapore market is forecasted to expand at a CAGR of 5.05% spanning 2026–2033.
  • Endometrial Adenocarcinoma held the leading position among By Type segments in 2024, based on market size.
  • Adenosquamous Carcinoma is projected to post the fastest growth rate, sustaining its position as the most attractive By Type segment during the forecast horizon.

Other Key Findings


  • In 2024, Singapore represented 0.43% of the overall global Uterine Cancer Market size.
  • United States is projected to lead the global Uterine Cancer Market size by 2033.
  • Across Asia Pacific, China is anticipated to hold the dominant position in market size by 2033.
  • South Korea is forecasted to expand at the fastest pace in Asia Pacific, attaining USD 82.51 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 26.98 Million
Market Size In 2033 USD 42.01 Million
Largest segment Endometrial Adenocarcinoma
Units Revenue in USD Million
CAGR 5.05% (2025-2033)
Segmnetation Covered
By Type
  1. Endometrial Adenocarcinoma
  2. Adenosquamous Carcinoma
  3. Papillary Serous Carcinoma
  4. Uterine Sarcoma
By Treatment
  1. Diagnosis
  2. Therapeutic Treatment
  3. Surgery
By End-Users
  1. Hospitals
  2. Diagnostic Centers
  3. Drug Stores
  4. Online Pharmacies
  5. Other End Users
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends